AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
84.69
+0.86 (1.03%)
At close: Oct 17, 2025, 4:00 PM EDT
85.14
+0.45 (0.53%)
After-hours: Oct 17, 2025, 7:58 PM EDT
AstraZeneca Employees
AstraZeneca had 92,900 employees as of December 31, 2024. The number of employees increased by 3,000 or 3.34% compared to the previous year.
Employees
92,900
Change (1Y)
3,000
Growth (1Y)
3.34%
Revenue / Employee
$608,192
Profits / Employee
$89,290
Market Cap
260.83B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
Dec 31, 2013 | 51,500 | -200 | -0.39% |
Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
Dec 31, 2007 | 67,400 | 600 | 0.90% |
Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
AZN News
- 17 hours ago - AstraZeneca's Datroway extends survival in aggressive breast cancer - Reuters
- 1 day ago - AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment - Reuters
- 2 days ago - TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps - Business Wire
- 2 days ago - US FDA expands use of Amgen, AstraZeneca's drug for sinus infection - Reuters
- 4 days ago - AstraZeneca unveils expanded manufacturing facility in Texas - Business Wire
- 6 days ago - AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO - Business Wire
- 7 days ago - Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump - Reuters
- 9 days ago - AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising. - Barrons